Statins in Epilepsy Management

Statins, widely prescribed as inhibitors of the enzyme HMG-CoA reductase, have emerged as promising adjuncts in the management of epilepsy. Beyond their lipid-lowering capacity, these agents exhibit anti-inflammatory, antioxidant and neuroprotective properties that may mitigate the processes underlying epileptogenesis and seizure recurrence. Preclinical models indicate that statins can preserve blood–brain barrier integrity, attenuate microglial activation and reduce aberrant synaptic reorganisation, notably mossy fibre sprouting in the hippocampus. Clinically, observational and interventional studies suggest that early statin administration after cerebral insults such as ischaemic stroke can lower the incidence of acute symptomatic seizures and potentially diminish the chronic progression to epilepsy. Ongoing efforts aim to delineate the optimal compound, dose and timing for antiepileptogenic efficacy, paving the way for repurposing these well-tolerated drugs in diverse epileptic syndromes.

Research from Nature Portfolio

Recent studies have demonstrated that initiation of statin therapy in the acute phase of ischaemic stroke is associated with a substantially reduced risk of early-onset seizures. Propensity-matched analyses indicate that patients receiving statins within days of stroke onset exhibit lower seizure rates during the first week, independent of traditional vascular risk factors. These findings underscore a potential role for statins in interrupting the cascade of inflammation and excitotoxicity that precipitates post-stroke epilepsy.

Statins in Epilepsy Management publication trend

The graph below shows the total number of articles in statins in epilepsy management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase inhibitors: A class of drugs that reduce cholesterol synthesis by blocking the rate-limiting enzyme in the mevalonate pathway.

Antiepileptogenic: Referring to interventions that prevent or delay the development of epilepsy following an initial insult.

Blood–brain barrier: A selectively permeable interface that regulates the passage of substances from the bloodstream into the central nervous system.

Mossy fibre sprouting: The growth of aberrant axonal projections in the dentate gyrus, often associated with chronic temporal lobe epilepsy.

References

1. Statins as antiepileptogenic drugs: Analyzing the evidence and identifying the most promising statin. Epilepsia (2022).
2. Lovastatin Modulates Glycogen Synthase Kinase-3β Pathway and Inhibits Mossy Fiber Sprouting after Pilocarpine-Induced Status Epilepticus. PLOS ONE (2012).
3. Statin treatment can reduce incidence of early seizure in acute ischemic stroke: A propensity score analysis. Scientific Reports (2020).
4. Statins in Neurological Disorders: Mechanisms and Therapeutic Value. The Scientific World JOURNAL (2009).
5. Liquid Crystalline Nanoparticles for Nasal Delivery of Rosuvastatin: Implications on Therapeutic Efficacy in Management of Epilepsy. Pharmaceuticals (2020).
6. Analyzing the causal relationship between lipid-lowering drug target genes and epilepsy: a Mendelian randomization study. Frontiers in Neurology (2024).